Gilead expands lenacapavir HIV PrEP access in Latin America; Cloudbreak IPO probed; Sironax gets $125M from Novartis; Circle ...
Stanford's Sergiu Pasca bred mice lacking cortex/hippocampus for the first time, replacing cells with human neurons, aiding ...
Investors are pumping $123 million into a tiny Michigan biotech that is resurrecting linsitinib for an eye disease that has ...
Centric Compounding recalls six lots of Glutathione, Myers' Cocktail and Tri-Immune Boost injections over endotoxin ...
HHS deputy secretary nominee Chris Klomp spars with Sen. Elizabeth Warren over secrecy around Trump's MFN drug pricing deals.
The Swiss pharma giant is ending work on VHB937/lifonebart in ALS, according to a letter from the company's clinical development team.
A501 Danon trial; Lilly pays $237M/program with QurCan; Connect's rademikibart fails Phase 2; Ascendis ends Novo $285M GLP-1 ...
Sionna Therapeutics announced it was laying off 46% of its staff as it seeks a way forward following an unexpected trial ...
Mental health experts urged the FDA at a hearing to set training and prescribing standards for psychedelic therapies.
AstraZeneca said Friday that its recently approved breast cancer drug Etcamah failed a late-stage trial designed to support a ...
GSK inks up to $750M deal for Chimagen's trispecific T cell engager in multiple myeloma, its second TCE pact with the China biotech.
FDA approves Scholar Rock's Isembyld (apitegromab) for SMA after Indiana manufacturing hurdles; shares jump 10% premarket.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results